RT Journal Article
SR Electronic
T1 Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society COVID-19 Dataset
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.24.20177576
DO 10.1101/2020.08.24.20177576
A1 Chari, Ajai
A1 Samur, Mehmet Kemal
A1 Martinez-Lopez, Joaquin
A1 Cook, Gordon
A1 Biran, Noa
A1 Yong, Kwee
A1 Hungria, Vania
A1 Engelhardt, Monika
A1 Gay, Francesca
A1 Feria, Ana García
A1 Oliva, Stefania
A1 Oostvogels, Rimke
A1 Gozzetti, Alessandro
A1 Rosenbaum, Cara
A1 Kumar, Shaji
A1 Stadtmauer, Edward A.
A1 Einsele, Hermann
A1 Beksac, Meral
A1 Weisel, Katja
A1 Anderson, Kenneth C.
A1 Mateos, María-Victoria
A1 Moreau, Philippe
A1 San-Miguel, Jesus
A1 Munshi, Nikhil C.
A1 Avet-Loiseau, Hervé
YR 2020
UL http://medrxiv.org/content/early/2020/08/31/2020.08.24.20177576.abstract
AB The primary cause of morbidity and mortality in patients with multiple myeloma (MM) is an infection. Therefore there is great concern about the susceptibility to the outcome of COVID-19 infected patients with multiple myeloma.This retrospective study describes the baseline characteristics and outcome data of COVID-19 infection in 650 patients with plasma cell disorders (98 outpatinets and 538 hospitilized patinets), collected from 10 countries by the International Myeloma Society to understand the initial challenges faced by Myeloma patients during COVID-19 pandemic. Descriptive statistics, univariate logistic regression, and multivariate analysis were performed for hospitalized MM patinets.The median age was 69 years, and nearly all patients (96%) had MM. Approximately 36% were recently diagnosed (2019-2020), and 54% of patients were receiving first-line therapy. Thirty-three percent of patients have died, with significant geographic variability, ranging from 27% to 57% of hospitalized patients. Univariate analysis identified age, ISS3, high-risk disease, renal disease, suboptimal myeloma control (active or progressive disease), and one or more comorbidities as risk factors for higher rates of death. Neither history of transplant, including within a year of COVID-19 diagnosis nor other anti-MM treatments were associated with outcomes. Multivariate analysis found that only age, high-risk MM, renal disease, and suboptimal MM control remained independent predictors of adverse outcome with COVID-19 infection.The management of MM in the era of COVID-19 requires careful consideration of patient and disease-related factors to decrease the risk of acquiring COVID-19 infection, while not compromising the disease control through appropriate MM treatment. This study provides the data to develop recommendations for the management of MM patients at risk of COVID-19 infection.Key PointsHigh but variable mortality for hospitalized MM patients (27% to 57%)Optimal MM control was associated with COVID-19 associated death for MM patinetsExplanation of novelty This study investigated the risk and outcome of COVID-19 infection in MM patients globally (10 countries)Competing Interest StatementAjai Chari is consultant/advisory board for Janssen, Celgene, Novartis, Amgen, Bristol Myers Squibb, Karyopharm, Sanofi Genzyme, Seattle Genetics, Oncopeptides, Millenium/Takeda, Antengene, Glaxo Smith Kline, Secura Bi. He has research funding from Janssen, Celgene, Novartis, Amgen, Pharmacyclics, Seattle Genetics, Millenium/Takeda. Joaquin Martinez-Lopez has received honoraria for participation in advisory boards from Novartis, Roche, BMS, Adaptive, Incyte, Amgen, and Janssen-Cilag. Katja Weisel has received honoraria and advisory board fromAdaptive Biotech, Amgen, BMS, Celgene, GSK, Janssen, Karyopharm, Sanofi, Takeda and research fundings from Amgen, Celgene, Sanofi, Janssen. Cara Rosenbaum has received honoraria from Akcea and Celgene and research funding from Amgen. Philippe Moreau has received honoraria and advisory boards from janssen, Celgene/BMS, Amgen, Sanofi, Abbive. Maria-Victoria Mateos has received honoraria for lectures and participation in advisory boards from Janssen, Celgene-BMS, Amgen, Takeda, Abbvie, GSK, Adaptive, Roche, Seatle Genetics, Pfizer, and Regeneron. Jesus San-Miguel has received honoraria for lectures and advisory boards from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Merck, Novartis, Takeda, Sanofi, and Roche. Nikhil C. Munshi is consultant for BMS, Janssen, Oncopep, Amgen, Karyopharm, Legened, Abbvie, Takeda and GSK; and on the board of directors and stock options Oncopep (NCM). Other authors declare no competing financial interests.Funding StatementNo external funding has been received to convey the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data in this analysis was provided to IMS by various groups and individuals following their local human subject data collection requirements and approval processes. Only de-identified data, with waivers of consent, were submitted in compliance with local ethics and governance approval of each center. This was a retrospective chart review without any direct patient contact for research purposes/questionnaires. The study did not involve any funding. Data from consecutive COVID-19 patients with plasma cell disorders that were diagnosed and managed per local guidelines were submitted from participating centers using a standardized data collection sheet.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the study can be obtained from International Myeloma Society.